MIT's Final Report Is Submitted to the AOAC for Listeria Performance Test Method Certification

SAN CLEMENTE, CA--(Marketwire - April 27, 2009) - Micro Imaging Technology, Inc. (OTCBB: MMTC) announced that it has submitted its Final Report to the AOAC Research Institute (AOAC RI) for Performance Test Method™ certification for the MIT 1000 System's identification (ID) of Listeria species. This bacterium causes the serious food-borne infection Listeriosis, which is recognized as an important public health issue in the United States, where annually an estimated 2,500 persons become seriously ill and is responsible for over 500 deaths.

The MIT 1000 System ("System") performs rapid and low cost microbial ID's in a process that is significantly different from all other ID methods and does not rely on chemical or biological agents, conventional processing, fluorescent tags, gas chromatography or DNA analysis -- the process is totally GREEN requiring only clean water and a sample of the unknown bacteria. The System's uniqueness, deriving microbial ID's from a proprietary database, and then coupled with AOAC RI's extensive evaluation criteria required several months of collaboration to develop a suitable Validation Protocol for the evaluation process -- which once commenced took almost one year to complete.

The Validation Protocol defined four specific requirements:

1) Document all procedures: including laboratory and sampling instructions, user's manual, and hardware and software specifications.

2) Prove the accuracy and repeatability of MIT's test method: The AOAC RI assigned the task to the U.S. Department of Agriculture's Advanced Research Service (USDA - ARS) and MIT laboratories. Each laboratory used the Validation Protocol procedures to conduct blind experiments on samples of unknown bacteria, meaning the user was not aware of the bacteria's ID. The collective accuracy from both laboratories, after a total of 136 tests, achieved 95 percent.

3) Verify the flexibility of the System: A total of 406 ruggedness tests were performed that provided an understanding of the System's ID's capabilities if the user's procedures are varied from those recommended by the Protocol and MIT.

4) Prepare a Final Report for the AOAC RI: The Final Report is submitted by the AOAC RI to independent expert reviewers who evaluate for PTM certification.

John Ricardi, MIT's Vice President and COO, stated "An AOAC PTM certification is a presumptive requirement for sales into the U.S. and most international food safety markets. Following Listeria certification, MIT's next goal is to achieve certifications for the ID of E.coli and Salmonella. The Test Protocols will be similar and, with the addition of E.coli and Salmonella, a single database will be created to ID the three pathogenic microbes that are responsible for most of the food bacterial contamination events worldwide. Additional microbes will be certified as required by the market."

"The food industry is MIT's initial targeted market where over $3 billion is spent in rapid ID testing annually and rising at 10 percent per year -- which should accelerate after all the recent food product contamination events. MIT is more than pleased with the results achieved during the AOAC PTM evaluation process for Listeria identification and gives a salute to both the AOAC RI and our own staff," stated Michael Brennan, MIT's Chairman and CEO.

MIT previously contracted with North American Science Associates, Inc. ("NAMSA"), an internationally recognized testing and process evaluating laboratory, to design and perform a verification test that compared the speed, accuracy and efficiency of MIT's System with conventional processes.

The comparative tests were in a double blind experiment, meaning that the NAMSA laboratory technicians, using the System and a well recognized alternative, were not aware of the various microbes' ID. NAMSA chose the industry standard gas chromatography-based MIDI Sherlock System ("MIDI") as the system to verify the accuracy of MIT's ID capabilities. MIT's System and procedures scored 98 percent correct in fifty ID tests. The MIDI system scored 80 percent and failed to ID, with several attempts, one pathogenic bacterium. NAMSA eventually employed a conventional biological testing method which matched the bacterium with MIT's ID. The MIDI system took hours per test and the biological testing method required days. MIT concluded each test with several minutes for sample preparation and an average of three minutes for System testing. The NAMSA Report is available from MIT.

About AOAC International and AOAC Research Institute:

AOAC INTERNATIONAL is a globally recognized, independent, not-for-profit association founded in 1884. To attain its vision of "worldwide confidence in analytical results," AOAC serves communities of the analytical sciences by providing the tools and processes necessary to develop voluntary consensus standards or technical standards through stakeholder consensus and working groups in which the fit-for-purpose and method performance criteria are established and fully documented. The AOAC Research Institute is part of AOAC INTERNATIONAL and maintains an up-to-the minute list of certified Performance Tested Methods which have been independently tested, rigorously evaluated and thoroughly reviewed by the AOAC Research Institute and its expert reviewers.

About Micro Imaging Technology:

MIT is a California-based public company that has developed and patented a rapid microbial ID system that can revolutionize the pathogenic ID process and annually save thousands of lives and tens of millions of dollars. The System ID's bacteria in minutes, not days, and at a significant per test cost savings when compared to any conventional method. Revenues for all rapid testing methods exceed $5 billion annually -- with food safety accounting for over $3 billion -- having expanded at a rate of 9.2 percent annually since 1998. Current growth projections are at 30 percent annually with test demands driven by major health, safety and homeland security issues.

The System is laser and optically based and uses the proven principles of light scattering in conjunction with proprietary PC-based software algorithms to ID microbes and create a proprietary database. MIT, through independent testing, has proven the ability with high accuracy to ID the most dangerous and pervasive pathogens; E. coli, Listeria, Salmonella, and Staphylococcus aureus (a.k.a. Staph) and twenty (20) other species of bacterium.

The MIT 1000 System has numerous ID applications including food quality control, clinical diagnostics, pharmaceutical quality assurance, semiconductor processing control and water quality monitoring. MIT has chosen to focus initial efforts on food quality control as recent events have created an urgent demand for quicker and cheaper testing -- demands that will promote a high-value return on any investment in MIT's technology.

Please visit our web site: www.micro-imaging.com

This release contains statements that are forward-looking in nature. Statements that are predictive in nature, that depend upon or refer to future events or conditions or that include words such as "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions are forward-looking statements. These statements are made based upon information available to the Company as of the date of this release, and we assume no obligation to update any such forward-looking statements. These statements are not guarantees of future performance and actual results could differ materially from our current expectations. Factors that could cause or contribute to such differences include, but are not limited to dependence on suppliers; short product life cycles and reductions in unit selling prices; delays in development or shipment of new products; lack of market acceptance of our new products or services; inability to continue to develop competitive new products and services on a timely basis; introduction of new products or services by major competitors; our ability to attract and retain qualified employees; inability to expand our operations to support increased growth; and declining economic conditions, including a recession. These and other factors and risks associated with our business are discussed from time to time within our filings with the Securities and Exchange Commission.

Contact Information: CONTACT: Michael Brennan Chairman Email: Telephone: (805) 557-0614